Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Forum
  • Discovery
  • About Us
    • Our Coverage
    • Team

ALK-Abelló

213.80 DKK

-0.93 %

Less than 1K followers

ALK B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.93 %
+2.10 %
-6.72 %
-6.47 %
+2.10 %
+47.55 %
+94.36 %
+73.96 %
+519.71 %

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen.

Read more
Market cap
47.64B DKK
Turnover
43.84M DKK
Revenue
6.31B
EBIT %
26.2 %
P/E
39.59
Dividend yield-%
0.75 %
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5.5
2026

Interim report Q1'26

20.8
2026

Interim report Q2'26

18.11
2026

Interim report Q3'26

All
Research
Webcasts
Press releases
ShowingAll content types
Press release19 hours ago

neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada

ALK-Abelló
HCA Morgenbørs 09/04 - Marked tager sig en pause ovenpå gårsdagens relief rally
Video4/9/2026, 7:23 AM by
Michael Friis, Philip Coombes

HCA Morgenbørs 09/04 - Marked tager sig en pause ovenpå gårsdagens relief rally

I dagens Morgenbørs ser vi ind i marked der tager sig en pause ovenpå gårsdagens relief rally. Herhjemme fokus på bl.a. Netcompany, Bioporto Alk Abello

TormHafniaNetcompany GroupNKTVestas Wind SystemsALK-AbellóBioPorto
Regulatory press release4/8/2026, 8:37 PM

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

ALK-Abelló

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release4/8/2026, 8:37 PM

Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer

ALK-Abelló
Regulatory press release4/1/2026, 8:05 AM

Tildeling af aktiebaserede langsigtede incitamentsinstrumenter til direktion og ledende medarbejdere

ALK-Abelló
Regulatory press release4/1/2026, 8:05 AM

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees

ALK-Abelló
Press release3/31/2026, 7:01 AM

EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis

ALK-Abelló
Regulatory press release3/16/2026, 5:37 PM

Annual General Meeting in ALK-Abelló A/S held on 16 March 2026

ALK-Abelló
Regulatory press release3/16/2026, 5:37 PM

Generalforsamling i ALK-Abelló A/S afholdt den 16. marts 2026

ALK-Abelló
Press release3/4/2026, 10:20 AM

New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors

ALK-Abelló
ALK: Præsentation af FY 2025 resultater (Optagelse)
Analyst Comment2/23/2026, 3:32 PM by
Michael Friis

ALK: Præsentation af FY 2025 resultater (Optagelse)

Vi havde i dag fornøjelsen af at møde EVP & CFO Claus Steensen Sølje samt VP & Head of IR Per Plotnikof, som præsenterede de finansielle resultater for 2025, fremgangen i Allergy+ strategien gennem 2025 og forventningerne til 2026. Eventet blev afsluttet med en Q&A-session.

ALK-Abelló
ALK – Præsentation af helårsresultater for 2025
Webcast2/23/2026, 12:30 PM

ALK – Præsentation af helårsresultater for 2025

ALK forventes at offentliggøre sit Q4 2025-regnskab den 20. februar 2026. Mandag den 23. februar kl. 13.30 kan du møde og stille spørgsmål til ALK’s EVP & CFO, Claus Steensen Sølje, og VP & Head of IR, Per Plotnikof, når de præsenterer årets finansielle resultater og højdepunkter.

ALK-Abelló
Dagens aktienyheder 23/02-2026: ALK
Analyst Comment2/23/2026, 9:13 AM by
Philip Coombes

Dagens aktienyheder 23/02-2026: ALK

Dagens aktienyheder 23/02-2026: ALK

ALK-Abelló
Regulatory press release2/20/2026, 1:54 PM

Annual General Meeting in ALK-Abelló A/S on 16 March 2026

ALK-Abelló
Regulatory press release2/20/2026, 1:54 PM

Ordinær generalforsamling i ALK-Abelló A/S den 16. marts 2026

ALK-Abelló
HCA Morgenbørs 20/02 - Fokus på regnskabsaktuelle ALK, samt Novo
Video2/20/2026, 9:18 AM by
Michael Friis, Rasmus Køjborg

HCA Morgenbørs 20/02 - Fokus på regnskabsaktuelle ALK, samt Novo

I dagens Morgenbørs ser vi ind i et marked der prøver at rebounde ovenpå en svag dag i går trukket af en blå ugle. Herhjemme er der fokus på regnskabsaktuelle ALK, samt Novo.

ALK-AbellóNovo NordiskMT Højgaard HoldingDanske BankNKTISSDFDS
Dagens aktienyheder 20/02-2026: ALK og Rovsing
Analyst Comment2/20/2026, 7:46 AM by
Philip Coombes

Dagens aktienyheder 20/02-2026: ALK og Rovsing

Dagens aktienyheder 20/02-2026: ALK og Rovsing

ALK-AbellóRovsing
Regulatory press release2/20/2026, 6:31 AM

Henriette Mersebach to step down as ALK’s head of R&D

ALK-Abelló
Regulatory press release2/20/2026, 6:31 AM

Henriette Mersebach fratræder som forskningsdirektør i ALK

ALK-Abelló
Regulatory press release2/20/2026, 6:17 AM

Annual report 2025: ALK delivers 15% revenue growth and 26% EBIT margin

ALK-Abelló
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.